Pathology of Lung Cancer
Over the past decade, the diagnosis, treatment and management of lung cancer has evolved substantially, in large part to the development of novel chemotherapeutic agents and targeted therapy in particular. As such, accurate classification of lung carcinomas from a histologic standpoint has become increasingly critical for appropriate patient management. Much of the focus of lung cancer pathology in the past decade has concentrated on adenocarcinoma. As such, the aim of this chapter will primarily focus on the evolution of this cancer subtype and review the recently published adenocarcinoma classification prepared jointly by the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society. Squamous cell carcinoma will also be discussed, particularly in regard to accurate discrimination from adenocarcinoma. The role of the pathologist in molecular testing will be reviewed, particularly as it relates to specimens obtained from radiologic procedures. Finally, given that the scope of this publication is radiation oncology, the histologic changes and evaluation of tumors which have undergone radiation and/or neo-adjuvant therapy will be discussed.
KeywordsEpidermal Growth Factor Receptor Epidermal Growth Factor Receptor Mutation Molecular Testing Mucinous Carcinoma Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
- Makimoto Y, Nabeshima K et al (2005) Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (</=20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi’s type C tumours). Histopathology 46(6):677–684PubMedCrossRefGoogle Scholar
- Sartori G, Cavazza A et al (2009) EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol 131(4):478–489PubMedCrossRefGoogle Scholar
- Scagliotti GV, Park K et al (2009b) Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer 45(13):2298–2303PubMedCrossRefGoogle Scholar
- Travis WD, Brambilla E et al (2004) Pathology and genetics: tumours of the lung, pleura, thymus and heart. IARC, LyonGoogle Scholar